Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studies
Rheumatology (Oxford). 2026 Oct 10:keag557. doi: 10.1093/rheumatology/keag557. Online ahead of print.ABSTRACTOBJECTIVES: To evaluate the long-term efficacy of bimekizumab in patients with psoriatic arthritis (PsA) across the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRA

